The S&P 500 closed out a brutal month in September with a weak finish but today is looking much better despite banking rumors and general anxiety. The bond market is recovering and the...
As for valuation, ZD currently trades at 7.2x forward EBITDA, about 20% lower than its 10-year average of 8.9x. I believe this 20% is warranted given the macro environment. Hence, I assumed...
The advances in cancer research on next-generation oncology devices and solutions have led to the development of various prognosis and treatment procedures for patients with a wide range of hematological and solid malignancies.
Immunotherapy...
Everyone in financial media is singing in unison, and the song they are all singing is a recessional for the recession — a hymn or musical piece sung while...
